JP2023511616A5 - - Google Patents

Info

Publication number
JP2023511616A5
JP2023511616A5 JP2022545799A JP2022545799A JP2023511616A5 JP 2023511616 A5 JP2023511616 A5 JP 2023511616A5 JP 2022545799 A JP2022545799 A JP 2022545799A JP 2022545799 A JP2022545799 A JP 2022545799A JP 2023511616 A5 JP2023511616 A5 JP 2023511616A5
Authority
JP
Japan
Application number
JP2022545799A
Other languages
Japanese (ja)
Other versions
JP7699595B2 (ja
JP2023511616A (ja
JPWO2021151865A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/051697 external-priority patent/WO2021151865A1/en
Publication of JP2023511616A publication Critical patent/JP2023511616A/ja
Publication of JP2023511616A5 publication Critical patent/JP2023511616A5/ja
Publication of JPWO2021151865A5 publication Critical patent/JPWO2021151865A5/ja
Application granted granted Critical
Publication of JP7699595B2 publication Critical patent/JP7699595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022545799A 2020-01-28 2021-01-26 統合的ストレス応答経路の調節因子 Active JP7699595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20154031.7 2020-01-28
EP20154031 2020-01-28
PCT/EP2021/051697 WO2021151865A1 (en) 2020-01-28 2021-01-26 Modulators of the integrated stress response pathway

Publications (4)

Publication Number Publication Date
JP2023511616A JP2023511616A (ja) 2023-03-20
JP2023511616A5 true JP2023511616A5 (https=) 2024-02-02
JPWO2021151865A5 JPWO2021151865A5 (https=) 2024-02-02
JP7699595B2 JP7699595B2 (ja) 2025-06-27

Family

ID=69374193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545799A Active JP7699595B2 (ja) 2020-01-28 2021-01-26 統合的ストレス応答経路の調節因子

Country Status (11)

Country Link
US (1) US20230125481A1 (https=)
EP (1) EP4096665A1 (https=)
JP (1) JP7699595B2 (https=)
KR (1) KR20220133252A (https=)
CN (1) CN114980894B (https=)
AU (1) AU2021213289A1 (https=)
BR (1) BR112022012643A2 (https=)
CA (1) CA3162526A1 (https=)
IL (1) IL294805A (https=)
MX (1) MX2022009243A (https=)
WO (1) WO2021151865A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201245B (zh) 2017-09-01 2024-04-05 戴纳立制药公司 化合物、组合物和方法
SG11202108552QA (en) * 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CN115190813B (zh) 2020-03-11 2024-10-15 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
EP4232153A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
RS66455B1 (sr) 2020-10-22 2025-02-28 Evotec Int Gmbh Modulatori puta integrisanog odgovora na stres
EP4232447A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
AU2023384649A1 (en) * 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4033412A1 (de) 1990-10-20 1992-04-23 Bayer Ag Fungizide mittel auf basis von heterocyclisch substituierten sulfonen
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
SG11201605757SA (en) * 2013-12-20 2016-08-30 Inst Drug Discovery Substituted amino triazoles, and methods using same
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR20190015492A (ko) 2016-06-08 2019-02-13 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학적 화합물
US20190298705A1 (en) 2016-06-08 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
BR112020000122A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
CA3071024A1 (en) 2017-08-09 2019-02-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN111201245B (zh) 2017-09-01 2024-04-05 戴纳立制药公司 化合物、组合物和方法
WO2019090090A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090074A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
WO2019090088A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501781A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023511616A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023546226A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021012003A2 (https=)